Biotech Unusual Volume: QLT (NASDAQ:QLTI), Sorrento Therapeutics (NASDAQ:SRNE), Aastrom Biosciences (NASDAQ:ASTM), 22nd Century Group (NYSEMKT:XXII)

Posted by on Mar 25, 2014

QLT (NASDAQ:QLTI) stock had its “neutral” rating reiterated by Zacksin a research note issued to investors on Tuesday, Analyst Ratings.Netreports. QLT Inc. (USA) (NASDAQ:QLTI) shares after opening at $5.60 moved to $5.69 on last trade day and at the end of the day closed at $5.61. Company price to cash ratio in past twelve months was calculated as 2.51. QLT Inc. (USA) (NASDAQ:QLTI) showed a negative weekly performance of -0.18 %.

Sorrento Therapeutics Inc (NASDAQ:SRNE) continues to strike the right cord with investors. Shares of the company have maintained their uptrend without showing any signs of fatigue. The uptrend gained energy following the announcement that industry veteran Mark Durand was joining the company’s board of directors. Sorrento Therapeutics Inc (NASDAQ:SRNE) shares fell -3.61% in last trading session and ended the day on $15.74. SRNE return on equity ratio is recorded as -112.80% and its return on assets is -92.60%. Sorrento Therapeutics Inc (NASDAQ:SRNE) yearly performance is 214.80%.

Aastrom Biosciences Inc (NASDAQ:ASTM)’s announced that Nick Colangelo, President and CEO of Aastrom, will present at the 2014 Regen Med Investor Day on March 26 at 3:15 p.m. EDT at the Metropolitan Club in New York City. Aastrom Biosciences Inc (NASDAQ:ASTM) shares moved down -21.73% in last trading session and was closed at $5.08 while trading in range of $2,004,700 – Aastrom Biosciences Inc (NASDAQ:ASTM) year to date (YTD) performance is 57.28%.

Share of 22nd Century Group Inc (NYSEMKT:XXII) is a different case, the fall in the stock price is seen by analysts as a perfect opportunity to buy as things are poised to get better from here. 22nd Century Group Inc (NYSEMKT:XXII) weekly performance is -39.41%. On last trading day company shares ended up $2.69. 22nd Century Group Inc (NYSEMKT:XXII) distance from 50-day simple moving average (SMA50) is -20.58%. Analysts mean target price for the company is $9.00.

Leave a Reply